340 related articles for article (PubMed ID: 9225947)
1. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
2. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.
Campbell AB; Kalman SM; Jacobs C
Cancer Treat Rep; 1983 Feb; 67(2):169-72. PubMed ID: 6681731
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.
Stewart DJ; Dulberg C; Molepo JM; Mikhael NZ; Montpetit VA; Redmond MD; Goel R
Cancer Chemother Pharmacol; 1994; 34(1):14-22. PubMed ID: 8174197
[TBL] [Abstract][Full Text] [Related]
4. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
[TBL] [Abstract][Full Text] [Related]
5. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
7. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E
Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050
[TBL] [Abstract][Full Text] [Related]
8. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.
Komaki K; Kusaba T; Tanaka M; Kado H; Shiotsu Y; Matsui M; Shiozaki A; Nakano H; Ishikawa T; Fujiwara H; Konishi H; Itoh Y; Matoba S; Tamagaki K
BMC Cancer; 2017 Feb; 17(1):144. PubMed ID: 28219368
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors.
Lagrange JL; Médecin B; Etienne MC; Pivot X; Cassuto-Viguier E; Renée N; Thyss A; Ferrero JM; Otto J; François E; Milano G
Pharmacotherapy; 1997; 17(6):1246-53. PubMed ID: 9399607
[TBL] [Abstract][Full Text] [Related]
10. Extract of Prunus persica flesh (PPFE) improves chemotherapeutic efficacy and protects against nephrotoxicity in cisplatin-treated mice.
Lee CK; Park KK; Hwang JK; Lee SK; Chung WY
Phytother Res; 2009 Jul; 23(7):999-1005. PubMed ID: 19140122
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations.
Kelsen DP; Alcock N; Young CW
Am J Clin Oncol; 1985 Feb; 8(1):77-80. PubMed ID: 4039530
[TBL] [Abstract][Full Text] [Related]
13. Renal tolerance to cisplatin in patients 70 years and older.
Cubillo A; Cornide M; López JL; Molina R; Feliu J; Espinosa E; Zamora P; de Castro J; Ordoñez A; González Barón M
Am J Clin Oncol; 2001 Apr; 24(2):192-7. PubMed ID: 11319297
[TBL] [Abstract][Full Text] [Related]
14. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
[TBL] [Abstract][Full Text] [Related]
15. Xanthorrhizol has a potential to attenuate the high dose cisplatin-induced nephrotoxicity in mice.
Kim SH; Hong KO; Hwang JK; Park KK
Food Chem Toxicol; 2005 Jan; 43(1):117-22. PubMed ID: 15582203
[TBL] [Abstract][Full Text] [Related]
16. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
[TBL] [Abstract][Full Text] [Related]
17. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity.
Reece PA; Stafford I; Russell J; Khan M; Gill PG
J Clin Oncol; 1987 Feb; 5(2):304-9. PubMed ID: 3806171
[TBL] [Abstract][Full Text] [Related]
18. Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Ahn JH; Kang YK; Kim TW; Bahng H; Chang HM; Kang WC; Kim WK; Lee JS; Park JS
Cancer Chemother Pharmacol; 2002 Aug; 50(2):104-10. PubMed ID: 12172973
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors Associated with Cisplatin-Induced Nephrotoxicity in Patients with Advanced Lung Cancer.
Miyoshi T; Misumi N; Hiraike M; Mihara Y; Nishino T; Tsuruta M; Kawamata Y; Hiraki Y; Kozono A; Ichiki M
Biol Pharm Bull; 2016; 39(12):2009-2014. PubMed ID: 27904042
[TBL] [Abstract][Full Text] [Related]
20. N-acetylcysteine improves renal hemodynamics in rats with cisplatin-induced nephrotoxicity.
Abdelrahman AM; Al Salam S; AlMahruqi AS; Al husseni IS; Mansour MA; Ali BH
J Appl Toxicol; 2010 Jan; 30(1):15-21. PubMed ID: 19681060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
